Scholarlink

Objectives <p>This study evaluated outcomes in eyes with retinal disorders with moderate to profound vision impairment after Excimer-Laser-Multiple-Light-Redirection (Excimer-MLR), a non-central, superficial and multifocal corneal photoablation for novel refractive neuroadaptive vision restoration.</p> Methods <p>Retrospective analysis of seven consecutively treated phakic and pseudophakic eyes followed for 18–24 months after unilateral Excimer-MLR.</p> Results <p>Control untreated fellow eyes: No significant change in median best-corrected distance visual acuity (BCDVA) or contrast sensitivity (CS).</p> <p>Treated eyes: Excimer-MLR temporarily modified corneal radii of curvature, defocused light at the PRL, decreased relative refractive error at multiple non-PRL retinal areas and shifted fixation. Median BCDVA improved significantly (<i>p</i> = 0.018) from baseline at all measured times between 3- and 24-months, with ≥15 ETDRS-letter-gain in 86% at 18–24 months. Preoperative mean and median BCDVA were 20/225 (range 20/100–20/604) and 0.98 logMAR, respectively. Mean BCDVA was 20/58, 20/68, 20/64, 20/60, mean (±SD) ETDRS-letter-gain was 28.9 (±10.6), 25.5 (±13.7), 26.8 (±14.9), 28.4 (±14.1) and median BCDVA was 0.40, 0.38, 0.48, 0.40 at 3, 6, 10–12, and 18–24 months, respectively. Median CS significantly improved from baseline. All treated eyes had preoperative-central scotomas that rapidly disappeared or became smaller and peripheral. Amsler grids were normal in 6/7 eyes at ≥18 months. Mean (±SD) retinal sensitivity average thresholds (RS) increased by 1.53 dB (±1.16) at 6 months. There were no changes in distance- or near-glasses and no Excimer-MLR-related adverse events.</p> Conclusion <p>Excimer-MLR, a rapid corneal procedure beneficially synergistic with retinal therapies, safely produced, without customisation, magnification or visual training, significant multiyear-visual improvements and increased retinal sensitivity in eyes with macular degeneration or surgically treated macular holes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes up to two years after Excimer-Laser-Multiple-Light-Redirection (Excimer-MLR) corneal treatment for retinal disorders with central visual loss

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Olivia N. Serdarevic,
  • Edward Q. Yavitz

摘要

Objectives

This study evaluated outcomes in eyes with retinal disorders with moderate to profound vision impairment after Excimer-Laser-Multiple-Light-Redirection (Excimer-MLR), a non-central, superficial and multifocal corneal photoablation for novel refractive neuroadaptive vision restoration.

Methods

Retrospective analysis of seven consecutively treated phakic and pseudophakic eyes followed for 18–24 months after unilateral Excimer-MLR.

Results

Control untreated fellow eyes: No significant change in median best-corrected distance visual acuity (BCDVA) or contrast sensitivity (CS).

Treated eyes: Excimer-MLR temporarily modified corneal radii of curvature, defocused light at the PRL, decreased relative refractive error at multiple non-PRL retinal areas and shifted fixation. Median BCDVA improved significantly (p = 0.018) from baseline at all measured times between 3- and 24-months, with ≥15 ETDRS-letter-gain in 86% at 18–24 months. Preoperative mean and median BCDVA were 20/225 (range 20/100–20/604) and 0.98 logMAR, respectively. Mean BCDVA was 20/58, 20/68, 20/64, 20/60, mean (±SD) ETDRS-letter-gain was 28.9 (±10.6), 25.5 (±13.7), 26.8 (±14.9), 28.4 (±14.1) and median BCDVA was 0.40, 0.38, 0.48, 0.40 at 3, 6, 10–12, and 18–24 months, respectively. Median CS significantly improved from baseline. All treated eyes had preoperative-central scotomas that rapidly disappeared or became smaller and peripheral. Amsler grids were normal in 6/7 eyes at ≥18 months. Mean (±SD) retinal sensitivity average thresholds (RS) increased by 1.53 dB (±1.16) at 6 months. There were no changes in distance- or near-glasses and no Excimer-MLR-related adverse events.

Conclusion

Excimer-MLR, a rapid corneal procedure beneficially synergistic with retinal therapies, safely produced, without customisation, magnification or visual training, significant multiyear-visual improvements and increased retinal sensitivity in eyes with macular degeneration or surgically treated macular holes.